LEGN
Legend Biotech Corporation
61.39
USD
This page is just a preview of the data found in TrendSpider’s full version
Legend Biotech Corporation stock is down -6.47% since 30 days ago. The next earnings date is Apr 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 November’s closed higher than October. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 06 Nov 15:40 | 19 Jan, 2024 | 75.00 | 5 | ||
| 06 Nov 15:40 | 19 Jan, 2024 | 75.00 | 5 | ||
| 06 Nov 15:40 | 19 Jan, 2024 | 75.00 | 5 | ||
| 06 Nov 17:40 | 15 Dec, 2023 | 65.00 | 7 | ||
| 06 Nov 18:01 | 15 Dec, 2023 | 65.00 | 7 | ||
| 06 Nov 19:33 | 15 Dec, 2023 | 65.00 | 7 | ||
| 07 Nov 14:30 | 16 Feb, 2024 | 45.00 | 0 | ||
| 07 Nov 14:46 | 19 Jan, 2024 | 70.00 | 2129 | ||
| 20 Nov 19:00 | 20 Dec, 2024 | 70.00 | 293 | ||
| 27 Nov 18:38 | 17 May, 2024 | 80.00 | 1 |
Legend Biotech Corporation engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for gastric cancer and T cell lymphoma.
